La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Sinopharm Group Résultats passés
Passé contrôle des critères 4/6
Sinopharm Group a connu une croissance annuelle moyenne de ses bénéfices de 9%, tandis que le secteur Healthcare a vu ses bénéfices augmenter de en hausse à 6.9% par an. Les revenus ont augmenté de en hausse à un taux moyen de 9.6% par an. Le rendement des capitaux propres de Sinopharm Group est 11.9% et ses marges nettes sont de 1.5%.
Informations clés
8.7%
Taux de croissance des bénéfices
8.1%
Taux de croissance du BPA
Healthcare Croissance de l'industrie | 11.3% |
Taux de croissance des recettes | 8.9% |
Rendement des fonds propres | 83.7% |
Marge nette | 1.5% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Ventilation des recettes et des dépenses
Comment Sinopharm Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 597,186 | 9,070 | 26,692 | -6 |
31 Mar 24 | 598,318 | 8,884 | 26,981 | -25 |
31 Dec 23 | 596,570 | 9,054 | 26,775 | 0 |
30 Sep 23 | 591,686 | 8,765 | 26,639 | 50 |
30 Jun 23 | 591,626 | 8,936 | 26,657 | 0 |
31 Mar 23 | 570,067 | 8,688 | 25,995 | 34 |
31 Dec 22 | 552,148 | 8,526 | 25,346 | 0 |
30 Sep 22 | 546,147 | 7,914 | 24,584 | 84 |
30 Jun 22 | 533,403 | 7,870 | 24,276 | 0 |
31 Mar 22 | 528,383 | 7,970 | 23,884 | 19 |
31 Dec 21 | 521,051 | 7,759 | 23,656 | 0 |
30 Sep 21 | 510,091 | 7,930 | 24,049 | 29 |
30 Jun 21 | 501,770 | 7,874 | 23,652 | 0 |
31 Mar 21 | 482,281 | 7,591 | 22,942 | 15 |
31 Dec 20 | 456,415 | 7,187 | 21,873 | 0 |
30 Sep 20 | 440,194 | 6,615 | 21,135 | 0 |
30 Jun 20 | 427,372 | 6,174 | 20,430 | 0 |
31 Mar 20 | 424,494 | 5,918 | 20,144 | -5 |
31 Dec 19 | 425,273 | 6,251 | 19,797 | 0 |
30 Sep 19 | 406,394 | 6,311 | 18,856 | 22 |
30 Jun 19 | 382,717 | 6,012 | 18,128 | 0 |
31 Mar 19 | 360,760 | 6,087 | 16,903 | 11 |
31 Dec 18 | 344,526 | 5,834 | 16,235 | 0 |
30 Sep 18 | 336,113 | 5,523 | 15,420 | 75 |
30 Jun 18 | 334,060 | 5,606 | 15,580 | 0 |
31 Mar 18 | 318,414 | 5,083 | 14,416 | 22 |
31 Dec 17 | 308,354 | 5,572 | 13,353 | 0 |
30 Sep 17 | 288,855 | 5,217 | 12,094 | 0 |
30 Jun 17 | 269,356 | 4,861 | 10,836 | 0 |
31 Mar 17 | 264,691 | 4,996 | 10,875 | 0 |
31 Dec 16 | 258,388 | 4,635 | 10,744 | 0 |
30 Sep 16 | 251,401 | 4,515 | 10,512 | 0 |
30 Jun 16 | 244,414 | 4,394 | 10,279 | 0 |
31 Mar 16 | 234,499 | 3,885 | 9,964 | 0 |
31 Dec 15 | 228,673 | 3,772 | 9,755 | 0 |
30 Sep 15 | 222,513 | 3,548 | 9,504 | 0 |
30 Jun 15 | 216,353 | 3,323 | 9,254 | 0 |
31 Mar 15 | 207,865 | 3,037 | 8,890 | 0 |
31 Dec 14 | 200,131 | 2,875 | 8,681 | 0 |
30 Sep 14 | 190,883 | 2,719 | 8,447 | 0 |
30 Jun 14 | 181,635 | 2,564 | 8,212 | 0 |
31 Mar 14 | 174,251 | 2,407 | 7,899 | 0 |
31 Dec 13 | 166,866 | 2,250 | 7,586 | 0 |
30 Sep 13 | 158,436 | 2,211 | 7,176 | 0 |
Des revenus de qualité: 1099 a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de 1099 (1.5%) sont supérieures à celles de l'année dernière (1.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: Les bénéfices de 1099 ont augmenté de 9% par an au cours des 5 dernières années.
Accélération de la croissance: La croissance des bénéfices de 1099 au cours de l'année écoulée ( 2.2% ) est inférieure à sa moyenne sur 5 ans ( 9% par an).
Bénéfices par rapport au secteur d'activité: La croissance des bénéfices 1099 au cours de l'année écoulée ( 2.2% ) n'a pas surpassé celle du secteur Healthcare 3.1%.
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de 1099 ( 83.7% ) est considéré comme exceptionnel.